36. Tamiflu (Oseltamivir): Unpublished ClinicalTrials.gov Records => 51% (23 out of 45)
Tamsulosin >75% unpublished
Dabigatran >80% unpublished
Agomelatine >80% unpublished
Liraglutide: 68.5% - three times as likely to be disseminated (3.1 to be spec
37. Re: Concerns over data in key dabigatran trial.
http://www.bmj.com/content/349/bmj.g4747/rr/778288
October 17, 2014.